Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Ramipril untuk hipertensi esensial pada dewasa

Penilaian teknologi kesehatan PTK-C09AA05 Draf untuk telaah Diperbarui 15 Juni 2026

1. Dampak anggaran

Dampak anggaran lima tahun. Nilai negatif berarti penghematan bagi pembayar.
-4.000-3.000-2.000-1.0000-53Tahun 1-249Tahun 2-706Tahun 3-1.572Tahun 4-2.964Tahun 5Tahun sejak obat mulai dijaminTambahan belanja per tahun (miliar rupiah)
TahunCakupanPasien diobatiTambahan belanjaKumulatif
Tahun 15%400.000-Rp 53,3 miliar-Rp 53,3 miliar
Tahun 215%1.200.000-Rp 248,6 miliar-Rp 302,0 miliar
Tahun 330%2.400.000-Rp 705,9 miliar-Rp 1,0 triliun
Tahun 450%4.000.000-Rp 1,6 triliun-Rp 2,6 triliun
Tahun 570%5.600.000-Rp 3,0 triliun-Rp 5,5 triliun

Indonesia adults ~190 million x hypertension prevalence 31.6% (SKI 2023) ~60 million; treated ~23.4% (Riskesdas 2018) ~14 million; ACEi-treated puskesmas subset eligible to switch from captopril ~8 million (estimate; needs Fornas dispensing validation).

2. Kapasitas layanan

Uraian berikut tersedia dalam bahasa Inggris.

DimensiPenilaian dan bukti
Workforce and competency capacity

The tier that would deliver the switch is the one that is adequately staffed, and the tier the current listing depends on is not. General practitioner density stands at 1.59 times the benchmark norm, while the referral cadres the hospital-exclusive listing routes through sit below it: internists at 0.87, cardiologists at 0.57 and registered nurses at 0.36. Supply is also unevenly placed rather than uniformly short, at 107.9 general practitioners per 100,000 in city districts against 31.3 in non-city districts.

  • General practitioner density is 1.59 times the benchmark norm. (NCD-D-10, 1.59)
  • Internist density is 0.87 times the norm and cardiologist density 0.57. (NCD-D-10, 0.57)
  • Registered-nurse density is 0.36 times the norm, the largest shortfall of the four cadres. (NCD-D-10, 0.36)
  • General practitioner headcount is 135,669, a density of 217.2 per 100,000 adults with hypertension. (NCD-D-10, 217.2)
  • 38.7 per cent of districts have no cardiologist and 84 per cent have no Sp.KKLP. (NCD-D-10, 38.7)
  • 23.5 per cent of districts are need-weighted under-served for general practitioners, holding 33 per cent of the hypertension population. (NCD-D-10, 33)
  • Workforce is counted as posts, not people: the licence-to-headcount ratio for general practitioners is 1.5. (NCD-D-10, 1.5)
Diagnostic and monitoring capacity

Blood pressure measurement and follow-up are already delivered at national scale, so the switch adds no new diagnostic requirement. 2,957 of 3,275 registered hospitals provide a hypertension service, covering 88.5 per cent of districts and 97 per cent of the population. Primary-tier density is thinner and uneven: 10,338 Puskesmas, one per 6,419 adults with hypertension, ranging from 9.8 per 100,000 in Jawa to 29.9 in Sulawesi.

  • 90.3 per cent of registered hospitals provide a hypertension-related service. (NCD-D-10, 90.3)
  • 88.5 per cent of districts hold at least one hypertension-service hospital, covering 97 per cent of the population. (NCD-D-10, 97)
  • There is one Puskesmas per 6,419 adults with hypertension nationally. (NCD-D-10, 6419)
  • 55 districts sit below half the national Puskesmas density per 100,000 adults with hypertension. (NCD-D-10, 55)
  • Puskesmas density ranges from 9.8 per 100,000 adults with hypertension in Jawa to 29.9 in Sulawesi. (NCD-D-10, 29.9)
  • The across-province Gini for hypertension-service hospitals per capita is 0.202. (NCD-D-10, 0.202)
Medicine supply and procurement capacity

The molecule is domestically manufactured and procurable today. Twenty-four registered products are active, from five Indonesian registrants, with the most recent registration dated 19 November 2025, and four stock keeping units carry a catalogue price. The constraint is not this medicine but the primary-tier basket around it: only 6 of the 30 WHO essential antihypertensives, 20 per cent, are available at the primary tier.

  • 24 registered ramipril products are active, all from Indonesian registrants. (C09AA05, 24)
  • Four stock keeping units carry an INAPROC catalogue price, median 398 rupiah a tablet. (C09AA05, 398)
  • 21 of 27 antihypertensives in Fornas, 78 per cent, have an active INAPROC listing. (NCD-D-10, 78)
  • Only 8 of 27, 30 per cent, have two or more stock keeping units, so brand choice is shallow. (NCD-D-10, 30)
  • 6 of 30 WHO essential antihypertensives, 20 per cent, are available at the primary tier. (NCD-D-10, 20)
Storage and cold-chain capacity

Not applicable to this product. Ramipril is a 5 mg oral tablet stored at room temperature; it introduces no cold chain, no controlled temperature transport and no additional storage requirement beyond the dry store every dispensing point already operates for the incumbent captopril tablet. This dimension is recorded as not applicable rather than assessed, because there is no capacity to measure, not because measurement is outstanding.

  • The product is a 5 mg oral tablet with no cold chain requirement. (C09AA05)
  • The comparator it replaces, captopril, is an oral tablet using the same storage. (C09AA05)
Referral and shared-care capacity

The referral architecture the medicine sits behind today is exactly what the decision proposes to change. The Fornas record lists it false at the primary tier and true at the referral tier, with a chronic-refill flag already set and a maximum of 30 tablets a month. The referral tier that arrangement depends on is thin: 38.7 per cent of districts have no cardiologist, 84 per cent have no Sp.KKLP, and the skill mix runs 83.6 general practitioners to each cardiologist.

  • Fornas lists ramipril at the referral tier only, with the chronic refill flag set and a 30 tablet monthly maximum. (C09AA05)
  • 38.7 per cent of districts have no cardiologist. (NCD-D-10, 38.7)
  • 13.6 per cent of districts are reached by a renal-hypertension subspecialist. (NCD-D-10, 13.6)
  • There are 83.6 general practitioners for each cardiologist nationally. (NCD-D-10, 83.6)
Information and reporting-system capacity

The instruments needed to carry a listing change and to monitor it exist and are documented. ARC's policy review identifies 22 hypertension and non-communicable disease regulations, of which 7 are national instruments and 8 are key national control instruments, drawn from a corpus of 12,454 regulations, alongside 3 clinical guideline and consensus documents. The chronic refill register the molecule already carries is the operational record a monitored rollout would read.

  • 22 hypertension and non-communicable disease regulations are identified, 7 of them national instruments. (NCD-D-10, 22)
  • 8 key national hypertension-control instruments are identified. (NCD-D-10, 8)
  • 3 clinical guideline or consensus documents for hypertension exist. (NCD-D-10, 3)
  • The regulatory corpus searched holds 12,454 regulations. (NCD-D-10, 12454)
  • The chronic refill flag is already set for this molecule, so a dispensing record exists. (C09AA05)

3. Kesiapan implementasi

Uraian berikut tersedia dalam bahasa Inggris.

DimensiPenilaian dan bukti
Clinical pathway and eligibility definition

The pathway change is the decision itself, not a precondition of it. The Fornas record lists ramipril false at the primary tier and true at the referral tier, with the chronic refill flag set and a maximum of 30 tablets a month. Moving the listing to the primary tier is a formulary substitution within a class already prescribed there, not a new indication or a new population. Three clinical guideline and consensus documents cover hypertension and would carry the change.

  • Fornas lists the molecule at the referral tier only, with the chronic refill flag set. (C09AA05)
  • The maximum prescription is 30 tablets a month, which matches once-daily dosing. (C09AA05)
  • 3 clinical guideline or consensus documents for hypertension exist to carry the change. (NCD-D-10, 3)
  • 22 hypertension and non-communicable disease regulations were identified, 7 of them national. (NCD-D-10, 22)
Training, supervision, and escalation protocol

Supervision, not prescribing skill, is the thin part. The prescriber cadre is already in place at 83.6 general practitioners per cardiologist and 1.4 nurses per general practitioner, and the class is familiar. What is missing is the primary-care specialist cadre that would supervise a pathway change: 84 per cent of districts have no Sp.KKLP. Headcount also overstates presence, since one clinician may hold several practice licences, at 1.5 licences per general practitioner and 2.5 per cardiologist.

  • 84 per cent of districts have no Sp.KKLP, the primary-care specialist cadre. (NCD-D-10, 84)
  • There are 83.6 general practitioners per cardiologist and 1.4 nurses per general practitioner. (NCD-D-10, 83.6)
  • The licence-to-headcount ratio is 1.5 for general practitioners and 2.5 for cardiologists, so posts overstate people. (NCD-D-10, 2.5)
Procurement and distribution readiness

Procurement is already in place and does not have to be built. Four stock keeping units carry a catalogue price at a median of 398 rupiah a tablet, supplied by five domestic registrants across 24 active registrations. Nationally 78 per cent of Fornas antihypertensives carry an active catalogue listing, so this molecule sits inside the normal procurement route rather than beside it.

  • Four INAPROC stock keeping units carry a price, median 398 rupiah a tablet. (C09AA05, 398)
  • 24 registered products are active from 5 Indonesian registrants. (C09AA05, 24)
  • 78 per cent of Fornas antihypertensives carry an active INAPROC listing. (NCD-D-10, 78)
  • Only 30 per cent of Fornas antihypertensives have two or more stock keeping units, so supply depth is shallow across the class. (NCD-D-10, 30)
Patient education and adherence support

Adherence is the mechanism the whole case rests on, and it is the input with the best evidence behind it. Days covered run 91.4 per cent on once-daily dosing against 83.2 per cent on two to three times daily, a difference of 8.2 percentage points with an interval of 4.0 to 18.0. The Indonesian dispensing measurement enters this as a coverage effect of 0.59, interval 0.41 to 0.86, rather than as a claim about the molecule.

  • Days covered are 91.4 per cent once daily against 83.2 per cent on two to three times daily. (C09AA05, 91.4)
  • The difference is 8.2 percentage points, interval 4.0 to 18.0. (C09AA05, 8.2)
  • The Indonesian dispensing factor is 0.59, interval 0.41 to 0.86, entered as a coverage effect. (C09AA05, 0.59)
  • The 30 tablet monthly maximum on the Fornas record matches once-daily dosing without a change of rule. (C09AA05, 30)
Safety surveillance and stewardship

Both arms are ACE inhibitors, so the safety question is a shift within a class rather than exposure to a new one, and the adverse event profile is represented once in the model through the cough, taste disturbance and rash block rather than folded into adherence. Stewardship capacity for the complication that matters most is narrow: the renal-hypertension subspecialty reaches 13.6 per cent of districts, and 47.2 per cent of hypertension spending already sits in hypertensive heart disease.

  • Both arms are ACE inhibitors, so the switch stays inside one class. (C09AA05)
  • Adverse-event burden is represented once, through the cough, taste and rash block, not by deflating adherence. (C09AA05)
  • Renal-hypertension subspecialists reach 13.6 per cent of districts. (NCD-D-10, 13.6)
  • Hypertensive heart disease is already 47.2 per cent of national hypertension spending. (NCD-D-10, 47.2)

4. Kesetaraan dan geografi

Uraian berikut tersedia dalam bahasa Inggris.

DimensiPenilaian dan bukti
Province and district variation

Control is distributed far more unequally than treatment, which is what makes this a targeting question and not only a coverage one. Across 514 districts the top decile reaches 11.44 per cent control against 1.03 per cent in the bottom, a ratio of 11.1, while treatment spans only 3.3-fold. Provinces run from 2.1 per cent in Papua Pegunungan to 13.19 in Sulawesi Utara. Thirty per cent of the variation sits between provinces rather than within them.

  • The control decile ratio across districts is 11.1, from 1.03 to 11.44 per cent. (NCD-D-02, 11.1)
  • The treatment decile ratio is only 3.3, from 11.3 to 37.4 per cent. (NCD-D-02, 3.3)
  • 332 districts sit below 5 per cent control, holding 41.9 million adults, 68 per cent of the hypertension population. (NCD-D-02, 68.0)
  • Provincial control runs from 2.1 per cent in Papua Pegunungan to 13.19 per cent in Sulawesi Utara. (NCD-D-02, 13.19)
  • The intraclass correlation is 0.30, so nearly a third of district variation is between provinces. (NCD-D-03, 0.3)
  • Deciles hold equal hypertension population, about 6.2 million adults each, so no decile is a small-sample artefact. (NCD-D-02)
Urban, rural, remote, and island access

Living outside a city is associated with lower control after adjustment for workforce, facilities, insurance and age. The standardised coefficient for a non-city district is -0.313 standard deviations, with a 95 per cent interval of -0.585 to -0.04 that excludes zero. The unadjusted cascade agrees: 2.8 per cent of rural adults with hypertension are at target against 5.5 per cent urban, and rural treatment runs 18.8 against 25.2 per cent.

  • A non-city district scores -0.313 standard deviations on control, interval -0.585 to -0.04. (NCD-D-03, -0.313)
  • Rural control is 2.8 per cent against 5.5 per cent urban. (NCD-D-02, 2.8)
  • Rural treatment is 18.8 per cent against 25.2 per cent urban. (NCD-D-02, 18.8)
  • Rural diagnosis is 22.2 per cent against 29.0 per cent urban, so the gap opens before treatment. (NCD-D-02, 22.2)
Socioeconomic and PBI status

The gradient runs the wrong way for the poorest, and it opens at diagnosis rather than at the tablet. The poorest fifth reach 2.8 per cent control against 7.6 per cent in the richest, a 2.7-fold gap, while prevalence is slightly higher among the poorest at 33.0 against 30.7 per cent. Insurance coverage predicts treatment, standardised coefficient 0.113 with an interval of 0.027 to 0.199, but not control, where the interval crosses zero. Subsidised members are 41.9 per cent of the insured hypertension cohort.

  • The poorest fifth reach 2.8 per cent control against 7.6 per cent in the richest. (NCD-D-02, 2.8)
  • Treatment runs 17.9 per cent in the poorest fifth against 28.3 per cent in the richest. (NCD-D-02, 17.9)
  • Hypertension is more common among the poorest, 33.0 against 30.7 per cent. (NCD-D-02, 33.0)
  • Insurance coverage predicts treatment at 0.113 standard deviations, interval 0.027 to 0.199. (NCD-D-03, 0.113)
  • Insurance coverage does not predict control: 0.023, interval -0.064 to 0.109. (NCD-D-03, 0.023)
  • Subsidised members are 41.9 per cent of the insured hypertension cohort and Class 3 wards 57 per cent. (NCD-D-10, 41.9)
Age and life-course distribution

Burden rises steeply with age while control does not keep pace, so the absolute number of uncontrolled older adults is where the switch would act. Prevalence reaches 44.8 per cent at ages 50 to 59 and 56.1 per cent at 60 to 69, against control of only 5.1 and 6.5 per cent. District median age is positively associated with control, 0.231 standard deviations with an interval of 0.127 to 0.336, which is consistent with older populations being in contact with care rather than with age protecting anyone.

  • Prevalence is 44.8 per cent at ages 50 to 59 and 56.1 per cent at 60 to 69. (NCD-D-02, 56.1)
  • Control is 5.1 per cent at 50 to 59 and 6.5 per cent at 60 to 69. (NCD-D-02, 5.1)
  • Treatment is 27.9 per cent at 50 to 59 and 32.5 per cent at 60 to 69. (NCD-D-02, 27.9)
  • District median age predicts control at 0.231 standard deviations, interval 0.127 to 0.336. (NCD-D-03, 0.231)
Sex and gender distribution

Women carry more of the disease and more of the treatment, and the two arms of the cascade nearly converge at the end. Prevalence is 35.6 per cent among women against 27.5 among men, diagnosis 30.5 against 20.8, treatment 26.4 against 17.8, but control 4.8 against 4.0. So women are far more likely to be in care and only slightly more likely to be at target, which means the loss between treatment and control is larger for women in absolute terms.

  • Prevalence is 35.6 per cent among women against 27.5 per cent among men. (NCD-D-02, 35.6)
  • Treatment is 26.4 per cent among women against 17.8 per cent among men. (NCD-D-02, 26.4)
  • Control is 4.8 per cent among women against 4.0 per cent among men, a far narrower gap than treatment. (NCD-D-02, 4.8)
  • Women are 55.8 per cent of the insured hypertension cohort. (NCD-D-10, 55.8)
Disability and comorbidity distribution

Uncontrolled hypertension has already become organ damage in a large share of the treated population, which is the group the switch is meant to keep out of hospital. Hypertensive heart disease, ICD I11, accounts for 47.2 per cent of national hypertension spending, against essential hypertension alone. Severe cases are 12.7 per cent of inpatient visits. Access to the subspecialty that manages renal complication is narrow, reaching 13.6 per cent of districts.

  • Hypertensive heart disease, I11, is 47.2 per cent of national hypertension spending. (NCD-D-10, 47.2)
  • Severe cases are 12.7 per cent of inpatient hypertension visits. (NCD-D-10, 12.7)
  • Renal-hypertension subspecialists reach only 13.6 per cent of districts. (NCD-D-10, 13.6)
  • National hypertension hospital spending rose from 4,616.6 billion rupiah in 2015 to 13,383.7 billion in 2024. (NCD-D-10, 13383.7)